Edition:
United States

GlycoMimetics Inc (GLYC.O)

GLYC.O on Consolidated Issue listed on NASDAQ Global Market

4.30USD
28 Apr 2017
Change (% chg)

$-0.21 (-4.66%)
Prev Close
$4.51
Open
$4.54
Day's High
$4.54
Day's Low
$4.24
Volume
29,388
Avg. Vol
42,075
52-wk High
$9.25
52-wk Low
$4.07

Latest Key Developments (Source: Significant Developments)

Glycomimetics Q4 loss per share $0.36
Wednesday, 1 Mar 2017 09:30am EST 

Glycomimetics Inc : Glycomimetics reports fourth quarter and year-end 2016 results . Glycomimetics Inc says qtrly loss per share $0.36 . Glycomimetics Inc says as of December 31, 2016, Glycomimetics had cash and cash equivalents of $40.0 million as compared to $46.8 million as of December 31, 2015 .Glycomimetics Inc says qtrly research and development expenses of $6.1 million versus $7.0 million for Q4 of 2015.  Full Article

GlycoMimetics posts Q3 loss of $0.34/share
Friday, 4 Nov 2016 09:15am EDT 

GlycoMimetics Inc: GlycoMimetics reports third quarter 2016 results and progress in clinical development . Qtrly loss per share $0.34 .Revenue for three-month periods ended September 30, 2016 and 2015 was not material.  Full Article

GlycoMimetics reports qtrly loss per share of $0.41
Thursday, 4 Aug 2016 04:15pm EDT 

GlycoMimetics Inc : GlycoMimetics reports second quarter 2016 results . Qtrly loss per share $0.41 .Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

Glycomimetics announces pricing of public offering
Friday, 17 Jun 2016 09:00am EDT 

Glycomimetics Inc : Says public offering of 3.30 million common shares priced at $6.10 per share .Glycomimetics announces pricing of public offering of common stock.  Full Article

Glycomimetics announces proposed public offering of common stock
Thursday, 16 Jun 2016 04:31pm EDT 

Glycomimetics : Glycomimetics announces proposed public offering of common stock .Intends to use proceeds to conduct planned clinical trials of GMI-1271, to fund research and development of preclinical pipeline, including drug discovery.  Full Article

Glycomimetics' GMI-1271 yields high remission rates in phase 1 portion of phase 1/2 clinical trial for AML
Friday, 10 Jun 2016 06:00am EDT 

Glycomimetics' Gmi : Dose escalation is complete and a GMI-1271 dose was identified for phase 2 testing . Results, showed an overall response rate of 47 percent among 19 patients .1271 yields high remission rates and favorable tolerability in phase 1 portion of phase 1/2 clinical trial for AML.  Full Article

FDA grants orphan drug designation to GlycoMimetics Inc's GMI-1271 for treatment of Acute Myleogenous Leukemia
Thursday, 14 May 2015 10:30am EDT 

GlycoMimetics Inc:Granted Orphan Drug designation to GMI-1271, a novel and proprietary E-selectin antagonist in the company's pipeline for treatment of patients with acute myeloid leukemia (AML).GlycoMimetics is currently recruiting patients in a Phase 1/2, open-label multicenter study to evaluate the safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in adult patients with AML.  Full Article

More From Around the Web

BRIEF-Glycomimetics Q4 loss per share $0.36

* Glycomimetics reports fourth quarter and year-end 2016 results